GRAIL, Inc. Q4 FY2024 earnings call

Key Points - Separated from Illumina in June 2024 and began public trading. - Grew U.S. Galleri revenue 45% YOY in 2024, selling over 137,000 tests. - Integrated Galleri into Quest Diagnostics test ordering system, enabling easy ordering for over 500,000 physicians and access at 7,400 Quest locations. - Rolled out enhanced version of Galleri in December 2024, which has a reduced panel size, automated workflow, and expanded lab capacity. - U.S. Military's TRICARE added Galleri to covered benefits for patients 50+ with elevated cancer risk. - Implemented restructure in 2024 to extend capital runway past major milestones, including modular PMA submission for Galleri FDA approval.

In the fourth quarter of 2024, GRAIL had revenue of $38.3 million. Screening revenue was $31.6 million, and development services revenue was $6.7 million. For the full year 2024, total revenue was $125.6 million. Screening revenue was $108.6 million, which was up 45% from 2023, and development services revenue was $17 million, a decrease of 6% from 2023. Fourth quarter screening revenue was up 39% year-over-year, driven by increased sales volumes, while development services revenue in Q4 '24 decreased 13% compared to Q4 2023.

Forward-Looking - In January 2025, guided cash burn for full-year 2025 to be no more than $320 million, a projected decrease of over 40% from 2024 cash burn. - Cash runway extends into 2028, enabling achievement of major milestones like readouts of registrational studies and completion of modular PMA submission.

Risks - Forward-looking statements are subject to risks and uncertainties. Actual results may differ materially from projected. Refer to GRAIL's SEC filings, including Risk Factors in the most recent 10-Q and upcoming 10-K, for detailed risks.

Q: Could you share more detail on how lower COGS per test from the new Galleri allows flexibility in pricing and if there's evidence of elasticity in demand?

A: The new version is about future proofing and scalability. We haven't done elasticity testing yet; it's early days and volumes need to increase for full scalability benefits.

Q: What's the status of the MCED legislation reintroduction?

A: Encouraged by reintroduction, bipartisan bicameral support remains strong, looking for the right vehicle to move it forward.

Q: Were the Quest collaboration and TRICARE news incorporated in the mid-January 2025 guide?

A: No change to 2025 guidance; these are sources of potential upside.

Q: What success looks like for PATHFINDER 2 study and timeline?

A: PATHFINDER 2 is evaluating Galleri's safety and performance in U.S. adults 50+ with elevated cancer risk. Main endpoints include test performance measures and safety. Readout will be part of Q1 2026 modular FDA submission.

Q: How could FDA submission and approval timeline impact cash burn?

A: Currently planning for first half of 2026 for PMA submission. Cash runway extends into 2028, providing cushion for potential delays.

Q: Impact of AI news on Q1 2025 results?

A: AI news is more of a longer-term opportunity; no impact expected in Q1 2025.